

## Results From Cardiovascular Study Published

Published on Surgical Products (<http://www.surgicalproductsmag.com>)

---

## Results From Cardiovascular Study Published

(BUSINESS WIRE)--Cardiovascular Systems, Inc. (CSI) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for vascular disease, today announced publication of 12-month results from its CALCIUM 360° study in the Journal of Endovascular Therapy.

CALCIUM 360° is a prospective, randomized, multi-center study of 50 patients (64 lesions), comparing one-year safety and efficacy of CSI's Diamondback 360° atherectomy device followed by percutaneous transluminal angioplasty (PTA), versus PTA alone, to treat calcified infrapopliteal lesions in patients with critical limb ischemia.

Based on the study results, the Diamondback 360° system provides significantly lower major serious adverse events (major amputation, all-cause mortality, and TLR/TVR) than PTA alone. The Diamondback arm demonstrated that lower balloon pressure is needed to achieve optimal dilatation ( $p < 0.001$ ), resulting in fewer procedural events for peripheral arterial disease (PAD) patients. At 12 months, the Diamondback 360° group was 93.3 percent free of major adverse events (major amputation, all-cause mortality and TLR/TVR) versus just 57.9 percent of the balloon angioplasty alone ( $p = 0.006$ ) group.

	<i>Diamondback 360°</i>	<i>Balloon Angioplasty</i>
Average maximum balloon pressures*	5.9 atms ( $p < 0.001$ )	9.4 atms
Procedural success ( $\leq 30\%$ residual stenosis)*	93.1%	82.4%
Dissections*	3.3%	11.4%
Bail-out stenting*	2 (6.9%)	5 (14.3%)
Freedom from revascularization*	93.3%	80.0%

## Results From Cardiovascular Study Published

Published on Surgical Products (<http://www.surgicalproductsmag.com>)

---

\*

Free of major adverse events**	93.3% (p=0.006)	57.9%
--------------------------------	--------------------	-------

(\*Per lesion \*\* Per patient)

According to David L. Martin, CSI president and CEO, "The CALCIUM 360° study demonstrates that our technology provides patients and physicians with a better therapy. It provides optimal balloon dilatation and significantly lowers complications. Our expanding clinical data set continues to demonstrate that the Diamondback 360° system is setting a new standard for treating calcified lesions."

The CALCIUM 360° study builds on CSI's history of clinical evidence and positive outcomes already seen in CSI's OASIS and COMPLIANCE 360° trials. Studies demonstrate sustained durability and low revascularization rates for CSI's orbital atherectomy systems with low-pressure PTA.

**Source URL (retrieved on 01/24/2015 - 11:40pm):**

[http://www.surgicalproductsmag.com/articles/2012/08/results-cardiovascular-study-published?qt-recent\\_content=0](http://www.surgicalproductsmag.com/articles/2012/08/results-cardiovascular-study-published?qt-recent_content=0)